Back in the early 1990s, a bile acid that was isolated from the bile of bears (
ursodeoxycholic acid, aka Ursodiol, UDCA) that seemed to be helpful in the long - term treatment of chronic liver disease.
Some forms of liver failure in humans improve or stabilize when patients are given oral
Ursodeoxycholic acid (aka ursodiol, UDCA) supplements.
Treatment for this disease includes supportive care, anti-inflammatory drugs and azathioprine and
ursodeoxycholic acid.
Ursodeoxycholic acid (ursodiol; Actigall or Urso) is another anti-inflammatory and bile facilitating drug that has been helpful.
At the present time, it appears that only the synthetic bile acid
ursodeoxycholic acid (Actigall or Ursodiol) delays progression of this disease.
The pioneering research led by academics from the Sheffield Institute of Translational Neuroscience (SITraN), in collaboration with scientists from the University of York, supports the fast - tracking of the drug
ursodeoxycholic acid (UDCA) for a clinical trial in Parkinson's patients.
Ursidae, excluding the giant panda, are also the only mammals with significant amounts of
ursodeoxycholic acid (UDCA), which is produced in the liver and stored in the gallbladder.